All the below links and tweets are in English.
取り急ぎ以下貼っておきます。
Massachusetts Vol.19 (corporations: Moderna)
Massachusetts Vol.20 (corporations: Biogen)
ツイッター検索で 上記2製薬会社各社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの
Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273): https://t.co/jpsGTOv9BQ pic.twitter.com/fo0XC7pCXo
— Moderna (@moderna_tx) August 28, 2020
.@TakedaPharma sets up deal to distribute @moderna_tx’s #COVID19 #vaccine in Japan: https://t.co/h7QCDUi89A
—#biomanufacturing #bio #biopharma #pharmaceutical #pharma #healthcare #manufacturing #coronavirus #pandemic pic.twitter.com/sTJPWEkjXv
— American Biomanufacturing (@BioMfg) September 2, 2020
Moderna to potentially supply Japan with 40M doses of COVID-19 vaccine @moderna_tx https://t.co/pRlHBWh3uk
— The Science Advisory Board (@ScienceBoard) August 28, 2020
American biotech company @moderna_tx has confirmed it is in discussions with #Japan's government over the potential purchase of 40 million or more doses of COVID-19 #vaccine.https://t.co/XKNJ7uC317
— The Jerusalem Post (@Jerusalem_Post) August 28, 2020
The #US-based biotech company #Moderna (@moderna_tx) has confirmed talks to supply 40 million doses of its potential #COVID19vaccine to #Japan. pic.twitter.com/qYDWaNTdQm
— IANS Tweets (@ians_india) August 30, 2020
“The [@moderna_tx] #vaccine candidate… would be distributed in Japan by @TakedaPharma, beginning in the first half of 2021… #Japan has already signed agreements with other drugmakers such as @Pfizer & @AstraZeneca, as well as local ones like #Shionogi & Co…” #COVID19 https://t.co/awQJyQhnpN
— Mark Warner (@MAAWLAW) August 28, 2020
COVID-19 Vaccine Pipeline https://t.co/z9QJ2v4RBj via @kyodo_english #WHO @moderna_tx #NIAID @InovioPharma @BioNTech_Group #ClinicalResearch "Even if overseas vaccines have success and received special regulatory approval, the supply in Japan will be limited"
— ClinicalBid (@ClinicalBid) June 30, 2020
We are proud to announce that we are working with @biogen Japan LTD. to create a system to respond faster and more accurately to questions from patients, the media, physicians & other constituents at its Medical Information Department (MID).
Read more: https://t.co/7R11MuIgCa
— Lexalytics (@Lexalytics) September 18, 2019
Program two "Gene Lab" @miraikan in Japan- Students worked on experiments w/electrophoresis and recombining DNA! #STEM #HandsOnScience pic.twitter.com/9AZ3JUGqgg
— Biogen (@biogen) March 21, 2017
Our Rare Disease treatment is now approved across the globe in Australia, Brazil, Canada, EU, Japan, Switzerland and the US #ProudMoments2017 pic.twitter.com/5lyBePTfYs
— Biogen (@biogen) December 22, 2017
Heading to Japan to be part of #WCN17 focused on the future of #neurology. Follow @Biogen for the latest! pic.twitter.com/A4yU2kFTci
— Biogen MS (@biogenms) September 15, 2017
Exciting moments w/ students @miraikan in Japan during "Gene Lab" hands-on experiment events – “E-coli glowing in the dark”! #STEM #Science pic.twitter.com/ak7wee6o7L
— Biogen (@biogen) March 13, 2017
Great to have @BiotechTour ambassadors & @miraikan representatives at our Japan office @sciencecenters #WBT2015 #STEM pic.twitter.com/MwPNSmJ9TH
— Biogen (@biogen) August 3, 2015
.@BiotechTour 2015 continues with it's next stop in Tokyo, Japan @miraikan (August 8 ceremony) http://t.co/12YAJjg4zn #WBT2015 #STEM
— Biogen (@biogen) July 28, 2015
An amazing day at @miraikan WBT festival! Thank you @biogen and @ScienceCenters for your support in Japan #WBT2015 pic.twitter.com/mqNeOMi9nU
— WorldBiotechTour (@BiotechTour) August 8, 2015
This year we celebrated our 40th anniversary with events in the U.S., Japan and Switzerland. Almost 2K employees, experts, physicians, patients and reporters were able to join us to reflect on the important moments that shaped our past, and our bright future. #ProudMoments2018 pic.twitter.com/iTnlHrhFZz
— Biogen (@biogen) December 11, 2018
#DRG epidemiology report estimates more than 15,000 people diagnosed with #SMA across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #spinalmuscularatrophy #RareDiseaseDay @biogen https://t.co/PguIonrUSW
— DRG Epidemiology (@DRG_Epi) March 5, 2020
#DRG epidemiology report estimates more than 15,000 people diagnosed with #SMA across the United States, Western Europe and Japan. Detailed report available now @DRGinsights #spinalmuscularatrophy #EAN2019 @biogen https://t.co/vNfzsxdEAd
— DRG Epidemiology (@DRG_Epi) July 3, 2019
#DRG epidemiology report estimates more than 35,000 diagnosed prevalent cases of #amyotrophiclateralsclerosis across the United States, Western Europe and Japan. Detailed report available now @DRGinsignts #ALS #WorldALSDay @biogen https://t.co/pE5tSpaPpw
— DRG Epidemiology (@DRG_Epi) June 24, 2019
More than 10 million people are living with #Alzheimersdisease across the United States, Western Europe and Japan. Stay tuned for more updates on #DRG global epidemiology data @DRGinsights @biogen #AlzheimersAwarenessMonth https://t.co/MmNdFkPrzQ
— DRG Epidemiology (@DRG_Epi) November 6, 2018
How about a deal with @SangamoTx to better exploit protein homeostasis? Hematology is unpartnered @ScienceAtBMS @bmsnews @JoeSzustakowski.
Partners include @sanofi @NovartisScience @pfizer #takeda @GileadSciences @KitePharma @biogen$SGMO $BMY $PFE $NVS $SNY $GILD $BIIB https://t.co/tJzQPwFTgB— biotech 2050 (@Biotech2050) July 30, 2020
Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx
— Open Targets (@targetvalidate) June 21, 2019
Takeda joins Open Targets drug discovery initiative. @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/XOHP4TPSpX pic.twitter.com/qPW97LuHPW
— Sanger Institute (@sangerinstitute) December 5, 2017
The Dementia Discovery Fund first launched in 2015 with $100 million in capital from a range of Big Pharma companies, the U.K. government and the non-profit Alzheimer's Research UK @Biogen @GSK @Johnson&Johnson @Lilly @Pfizer @Takeda @ARUK @DHSCgovukhttps://t.co/tdtENajGGx
— The Dementia Discovery Fund (@TheDDFund) August 9, 2018
.@TheDDFund $350M raise included $60M from @AARP as part of its #DisruptDementia initiative; fund spearheaded by #biopharma group that included @biogen @LillyPad @GSK @JNJNews Otsuka @pfizer @TakedaPharma
— BioWorld (@BioWorld) June 25, 2018
Former @biogen R&D guy @michael_gilman has a new biotech today, Obsidian, founded in 2015 by Atlas. A $50M Series A round was led by GV, the venture arm of Alphabet, & includes Atlas and the venture arms of Takeda and Amgen. by @BosBizMax https://t.co/HPYNg8DZaA
— Don Seiffert (@BosBizDon) December 6, 2017
#Biotech Industry in #Boston Reacts to #Coronavirus, Implements Containment Measures | @Biogen execs instructed to quarantine and isolate themselves from loved ones, and @Takeda implementing work-from-home for workforce | #COVID19 #SARSCoV2 #2019nCoV https://t.co/80oCHVVDbN
— Patrick Henry Warren (@phwarren360) March 9, 2020
https://twitter.com/bmd_congress/status/1165337983094067201
Great news that Takeda has joined the Open Targets drug discovery initiative. More here: https://t.co/XOHP4TPSpX @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/8SFnDO41B2
— Sanger Institute (@sangerinstitute) December 5, 2017
ADI would like to thank our supporters whose generosity enabled us to run yet another successful #WorldAlzMonth campaign; in particular, Acadia Pharmaceuticals, @biogen, @JanssenUK, @Lundbeck, Otsuka & @Roche. Thank you! pic.twitter.com/Pej52CpUhz
— ADI (@AlzDisInt) October 2, 2020
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus | @Roche @Eisaius @Biogen @Quest @HMHNewJersey @hallnursing #Nutley #NewJersey #Cambridge #Massachusetts #Biotech #neurodegenerative #diabetes #cancer #alzheimer #parkinson https://t.co/ce0EkdSrJF
— Aspen Biosciences (@aspenbio) August 12, 2020
Eisai is creating a new US corporate, R&D HQ in Roche’s old Nutley, NJ campus | @Roche @Eisaius @Biogen @Quest @HMHNewJersey @hallnursing #Nutley #NewJersey #Cambridge #Massachusetts #Biotech #neurodegenerative #diabetes #cancer #alzheimer #parkinson https://t.co/IkXPDuB59M
— Pharm2Market (@pharm2market) August 12, 2020
Biogen and Eisai Complete the Submission of BLA to the US FDA for Aducanumab to Treat Alzheimer’s Disease @biogen @EisaiUS https://t.co/A9YmZfSPUW pic.twitter.com/rGx3wODNiz
— PharmaShots – Incisive news in 3 shots (@Pharmashot) July 9, 2020
Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer’s Disease @biogen https://t.co/nSOsjsoRZo pic.twitter.com/WrFji1EsGZ
— PharmaShots – Incisive news in 3 shots (@Pharmashot) March 22, 2019
Biogen, Eisai seek priority US #FDA review of #Alzheimer's drug @biogen https://t.co/1w1SRBawS1 pic.twitter.com/1rd7XK4AdE
— Market Intelligence: Healthcare (@SPGMIHealthcare) July 9, 2020
Global #Alzheimers #Drugs Market 2019 — Eisai Pharmaceuticals, @Allergan, Amgen, @Biogen https://t.co/g6tC6YC5KB
— Marketstudy (@Marketstudy1) October 25, 2019
Biogen, Eisai revive plans for Alzheimer’s drug #Alzheimers @biogen https://t.co/0ChzgxABqB
— Pharmacy Business (@PharmacyBiz) October 24, 2019
This is incredibly disappointing news, but just another reason we have to keep up the fight. Alzheimer's is relentless, so are we. #endalz @biogen @eisai
Biogen, Eisai End Two Late-Stage Trials for Alzheimer’s Treatment https://t.co/skleIwPUcw
— Carey Ann Comeau (@careyanncomeau) September 17, 2019
Due to unfavorable risk-benefit, @Eisai_SDGs & @biogen discontinue Ph3 #clinicaltrials of #elenbecestat vs early #Alzheimers#BACE inhibitor was studied in patients w/ mild #cognitive impairment or mild AD + #amyloid pathologyhttps://t.co/MPKXpGK141#neuroscience #dementia pic.twitter.com/ik4Dc4JCpH
— DDNews Online (@DDNewsOnline) September 13, 2019
Eisai kickstarting alternate Alzheimers’ drug after failure of Aducanumab: https://t.co/ccyHcYCEKl @FierceBiotech @EisaiUS @Biogen #Alzheimers #mentalhealth #drugdiscovery #medicine
— NCBCenter (@NCBCenter) March 27, 2019
@Eisai_SDGs, @biogen kick-off phase 3 testing early #Alzheimer's disease antibody, amid dropping #aducanunab trial https://t.co/jmNie2FFf8 pic.twitter.com/8PFtoy4mgr
— Pharmacutical Daily (@PharmacDaily) March 22, 2019
https://twitter.com/HeidiCreighton/status/1109772708148113409
https://twitter.com/HeidiCreighton/status/1109064555542523906
Disappointing news, @biogen and Eisai have announced the decision to discontinue the EMERGE and ENGAGE Phase III clinical studies of #aducanumab in #Alzheimer’s diseasehttps://t.co/b0pCqyNZFc pic.twitter.com/uZjfSsaCwL
— Alzheimer Europe (@AlzheimerEurope) March 21, 2019
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease https://t.co/9aYlZeFYCV @biogen @EisaiUS More life science business news at [LSUS] at https://t.co/WILuBJwPqp pic.twitter.com/a4tJEPaJ1m
— [iito] Life Science (@iitoLifeScience) March 21, 2019
“We used to have to squint and look at things to feel like, ‘OK, maybe this could work.’ I think this is really giving us a real feeling that we’re making a lot of progress,” PMC's Dr. David Wolk told @whyy regarding the @biogen/Eisai research results. https://t.co/cKjfs4vtDN
— Penn Memory Center (@Penn_Memory) July 31, 2018
Eisai Co. & @Biogen revealed data showing their experimental drug slows the progression of #Alzheimers, but experts like PMC Co-Director @jasonkarlawish say they would like to see a larger, longer study conducted to further assess risks and benefits. @WSJ https://t.co/L1e06YnWjn
— Penn Memory Center (@Penn_Memory) July 30, 2018
.@biogen and Eisai's #Alzheimers drug demonstrated in a clinical trial that it significantly slowed cognitive decline and more for #pharma #marketers to know. $BIIB $GILD $AMGN #healthcare #HealthInsurance https://t.co/QebzaE0NAb pic.twitter.com/zHPfvrOsBx
— MM+M Magazine (@MMMnews) July 26, 2018
News for #pharma #marketers: Thurs, July 26
– @biogen and Eisai's #Alzheimers drug slows cognitive decline
– @GileadSciences CEO to step down
– @Amgen #migraine treatment faces difficulties with insurers$BIIB $GILD $AMGN #healthcare #HealthInsurance https://t.co/QebzaDJcID pic.twitter.com/p8HskyIm4K— MM+M Magazine (@MMMnews) July 26, 2018
.@Biogen and Japanese drugmaker Eisai created a surge in hope for an experimental #Alzheimers drug called BAN2401, after the companies announced positive results in a late-stage trial. But did the market overreact to the #data? #pharma #healthcare https://t.co/FlAEq43bX5 pic.twitter.com/KWgtEpyMsO
— MM+M Magazine (@MMMnews) July 14, 2018
Eisai and Biogen's Alzheimer's drug slows progression in Phase 2 trials https://t.co/q34CgTkBpR #AlzheimersDisease #Alzheimers #Phase2 @EisaiUS @biogen
— Pharmafocus (@Pharmafocus) July 26, 2018
Looks like Investors, analysts remain to be convinced over @EisaiUS @Biogen's #BAN2401 in #AlzheimersDisease even after more details of promising Phase II data
Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical https://t.co/YYao6VbYT2
— Ian Haydock (@ScripIanHaydock) July 26, 2018
Results of @Biogen and #Eisai clinical trial show #Alzheimers treatment reduced buildups of amyloid plaque in the brain by 93% and slowed progression of the disease 30-47% https://t.co/NIOMoy3SYG $BIIB pic.twitter.com/fwfkvkWzSM
— Jeff Cotrupe (@jeffcotrupe) July 25, 2018
Clinical trial results are in! Eisai & Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months @biogen https://t.co/kaoS6IQKJR pic.twitter.com/4glbrp4Hc7
— Neural Cell News (@NeuralCell) July 13, 2018
Eisai and @Biogen announce positive phase 2 Alzheimer’s data on BAN2401 anti-amyloid beta protofibril antibody. Patients exhibited slowdown in symptoms and reduced plaque in the brain. https://t.co/19Vp6MgFLI Good news and verification of amyloid beta as a therapeutic target
— Upperton (@UppertonLtd) July 12, 2018
We're closer than ever to treating #Alzheimer's with two drugs from @Biogen and @Eisai that do what #BigPharma hasn't been able to yet. https://t.co/uEccuWjPRX
— Tech2 (@tech2eets) July 10, 2018
@EisaiUS and @biogen Phase 2 trial for BAN2401 in #Alzheimers #patients, GlobalData figures say the global Alzheimer’s market will reach $14.8bn by 2026, so Eisai and Biogen can still expect to achieve significant sales for their product. https://t.co/mNRhbYywLU
— GlobalData Pharma (@Pharma_GD) July 6, 2018
@biogen @EisaiUS news – a win for the #amyloid hypothesis "BAN2401 Results Validate Eisai/Biogen's Faith In Alzheimer's Amyloid Tack" via @PharmaScrip #Alzheimers pic.twitter.com/b7Srr8hCf6
— OptimumComms (@OptimumComms) July 6, 2018
https://twitter.com/akalali/status/1015103726577639424
#Eisai – #Biogen to advance #Alzheimers drug, provide fresh hope https://t.co/UHQLpoVTGA #ETHealthworld @ETHealthWorld @biogen #BAN2401 #AlzheimersDisease #pharma
— Plexus Ventures (@PlexusVentures) July 25, 2018
@biogen takes up option to co-develop #Eisai #AD drug https://t.co/mfwmLP2VXu @PharmaTimes #AlzheimersDisease #aducanumab
— Plexus Ventures (@PlexusVentures) October 25, 2017
Eisai sells RTP facility to @Biogen; results in 35 layoffs http://t.co/iqBdzh1Ski pic.twitter.com/m7S3Xolkzy
— Boston Business Journal (@BosBizJournal) July 16, 2015
#Leukemia_Therapeutics_Market: Growing at a CAGR of 6.6% over the forecast period of 2019-2025.
For More Details: https://t.co/jmnagRx2bn @Celgene @Eisai_SDGs @SanofiGenzyme @bmsnews @Novartis_AG @biogen @Roche @GSK @pfizer pic.twitter.com/BtaRV399Eb— Infinium Global Research (@infiniumglobal1) August 24, 2019
Very interesting consensus white paper from @MichaelJFoxOrg: A proposed roadmap for #Parkinsons proof of concept clinical trials investigating compounds targeting alpha synuclein – @biogen @VAInstitute @Eisai @LumosPharma @JCedarbaum @BrundinPatrikhttps://t.co/5h4mu4a70F pic.twitter.com/ozaqisV10M
— ScienceofParkinsons (@ScienceofPD) November 8, 2018
Would this treatment resolve these issues from #Inflammation as well?#Dementia @nih_nhlbi @biogen @EisaiUS @eisai @HopkinsMedNewshttps://t.co/V7k8ZwqTBd pic.twitter.com/79WFvREHz3
— BW (@fxrseen) July 6, 2018
